These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 6381006)

  • 21. 36 months continuous subcutaneous insulin infusion (CSII) in insulin dependent diabetes (IDDM)--influence on early stages of retinopathy, nephropathy and neuropathy--psychological analysis.
    Bibergeil H; Hüttl I; Felsing W; Felsing U; Seidlein I; Herfurth S; Dabels J; Reichel G; Lüder C; Albrecht G
    Exp Clin Endocrinol; 1987 Aug; 90(1):51-61. PubMed ID: 3666060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo study.
    Dahl-Jørgensen K; Brinchmann-Hansen O; Hanssen KF; Ganes T; Kierulf P; Smeland E; Sandvik L; Aagenaes O
    Br Med J (Clin Res Ed); 1986 Nov; 293(6556):1195-9. PubMed ID: 3096429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolic control in newly kidney transplanted insulin-dependent diabetics: improvement by insulin pump treatment (CSII).
    Schmitz O; Sorensen SS; Alberti KG; Orskov H; Hansen HE
    J Diabet Complications; 1987; 1(3):81-6. PubMed ID: 2969910
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Continuous subcutaneous insulin infusion treatment in insulin-dependent diabetic patients: a comparison with conventional optimized treatment in a long-term study.
    Calabrese G; Bueti A; Santeusanio F; Giombolini A; Zega G; Angeletti G; Cartechini MG; Brunetti P
    Diabetes Care; 1982; 5(5):457-65. PubMed ID: 7188333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overnight metabolic control with bedtime injection of intermediate-acting insulin or continuous subcutaneous insulin infusion.
    Olsson PO; Arnqvist H; Von Schenck H; Ottosson AM
    Diabetes Care; 1987; 10(6):702-6. PubMed ID: 3322726
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma immunoreactive somatostatin response to arginine after glycemic control with continuous subcutaneous insulin infusion in type I diabetics.
    Kobayashi T; Sawano S; Itoh T; Kosaka K
    Diabetes Care; 1987; 10(3):286-92. PubMed ID: 2885161
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes.
    Pickup J; Keen H
    Diabetes Care; 2002 Mar; 25(3):593-8. PubMed ID: 11874953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic alterations after a two-hour nocturnal interruption of a continuous subcutaneous insulin infusion.
    Scheen A; Castillo M; Jandrain B; Krzentowski G; Henrivaux P; Luyckx AS; Lefèbvre PJ
    Diabetes Care; 1984; 7(4):338-42. PubMed ID: 6381007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Continuous subcutaneous insulin infusion in adults: glycemic advantage is predicted by venous plasma C-peptide concentrations.
    Rodger NW; Dupre J; Canny CL; Brown WF
    Diabetes Care; 1985; 8(5):447-55. PubMed ID: 3902423
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A crossover comparison of continuous subcutaneous insulin infusion (CSII) against multiple insulin injections in insulin-dependent diabetic subjects: improved control with CSII.
    Home PD; Capaldo B; Burrin JM; Worth R; Alberti KG
    Diabetes Care; 1982; 5(5):466-71. PubMed ID: 6765222
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Experiences of continuous subcutaneous insulin infusion in pregnant women with type 1 diabetes during delivery from four Italian centers: a retrospective observational study.
    Fresa R; Visalli N; Di Blasi V; Cavallaro V; Ansaldi E; Trifoglio O; Abbruzzese S; Bongiovanni M; Agrusta M; Napoli A
    Diabetes Technol Ther; 2013 Apr; 15(4):328-34. PubMed ID: 23537417
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of long-term near-normoglycemia on the progression of diabetic nephropathy.
    Ciavarella A; Vannini P; Flammini M; Bacci L; Forlani G; Borgnino LC
    Diabete Metab; 1985 Feb; 11(1):3-8. PubMed ID: 3884404
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Continuous subcutaneous insulin infusion (CSII) in treating young diabetic patients].
    Buczkowska EO; Dworzecki T; Wiedermann G; Malanowicz B; Szot D
    Przegl Lek; 2005; 62(1):49-53. PubMed ID: 16053222
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sustained normoglycemia and remission phase in newly diagnosed type I diabetic subjects. Comparison between continuous subcutaneous insulin infusion and conventional therapy during a one year follow-up.
    Edelmann E; Walter H; Biermann E; Schleicher E; Bachmann W; Mehnert H
    Horm Metab Res; 1987 Sep; 19(9):419-21. PubMed ID: 3319859
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion.
    Raz I; Weiss R; Yegorchikov Y; Bitton G; Nagar R; Pesach B
    Clin Ther; 2009 May; 31(5):980-7. PubMed ID: 19539098
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Implementation of treatment protocols in the Diabetes Control and Complications Trial.
    Diabetes Care; 1995 Mar; 18(3):361-76. PubMed ID: 7555480
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The improved response in endogenous insulin due to continuous subcutaneous infusion of insulin therapy in juvenile diabetes.
    Amemiya S; Kato K; Asayama K
    Tohoku J Exp Med; 1983 Dec; 141 Suppl():713-7. PubMed ID: 6393445
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Benefits of continuous subcutaneous insulin infusion in type 1 diabetes previously treated with multiple daily injections with once-daily glargine and pre-meal analogues.
    Torres I; Ortego J; Valencia I; García-Palacios MV; Aguilar-Diosdado M
    Exp Clin Endocrinol Diabetes; 2009 Sep; 117(8):378-85. PubMed ID: 19629931
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insulin production rate in normal man as an estimate for calibration of continuous intravenous insulin infusion in insulin-dependent diabetic patients.
    Waldhäusl WK; Bratusch-Marrain PR; Francesconi M; Nowotny P; Kiss A
    Diabetes Care; 1982; 5(1):18-24. PubMed ID: 6754299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. U-100 insulin gives some protection against metabolic deterioration due to CSII interruption.
    Scheen AJ; Henrivaux P; Jandrain B; Lefèbvre PJ
    Diabetes Care; 1987; 10(6):707-11. PubMed ID: 3322727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.